亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Sustained Efficacy and Safety in Adult and Pediatric Patients with Transfusion-Dependent β-Thalassemia up to 9 Years Post Treatment with Betibeglogene Autotemcel (Beti-cel)

地中海贫血 医学 输血 儿科 内科学
作者
Mark C. Walters,Alexis A. Thompson,Timothy S. Olson,John B. Porter,Jennifer Schneiderman,Suradej Hongeng,Andreas E. Kulozik,Marina Cavazzana,Martin G. Sauer,Adrian J. Thrasher,Isabelle Thuret,Ashutosh Lal,John E.J. Rasko,Evangelia Yannaki,Shamshad Ali,Ge Tao,Himal L. Thakar,Ami A. Deora,Katiana Gruppioni,Richard A. Colvin,Franco Locatelli,Janet L. Kwiatkowski
标识
DOI:10.1016/j.jtct.2023.12.301
摘要

Beti-cel gene therapy addresses the underlying cause of transfusion-dependent β-thalassemia (TDT) via autologous transplantation of hematopoietic stem and progenitor cells transduced with a functional version of the β-globin gene to produce normal adult hemoglobin (Hb), HbAT87Q. Here, we report long-term outcomes from patients treated with beti-cel. Patients with TDT who completed either a phase 1/2 (HGB-204 [NCT01745120]; HGB-205 [NCT02151526]) or phase 3 (HGB-207 [NCT02906202]; HGB-212 [NCT03207009]) beti-cel parent study and subsequently participated in the long-term, 13-year follow-up study LTF-303 (NCT02633943) were included. Efficacy (including transfusion independence [TI], defined as a weighted average Hb ≥9 g/dL without packed red blood cell transfusions for ≥12 months) and safety are reported through last follow-up. Key outcomes were also examined based on patient age at enrollment (pediatric: <18 years; adult: ≥18 years). As of January 30, 2023, 63 patients (median [range] age: 17 [4-35] years) had received beti-cel and enrolled in LTF-303, with a median (range) follow-up of 60.1 (23.8-109.5) months. In phase 3 studies, which used the commercial drug product (DP) manufacturing process, 37/41 (90.2%) patients achieved and maintained TI through last follow-up (up to 6 years; Table). In phase 1/2 studies that used an older DP manufacturing process, 15/22 (68.2%) patients achieved TI, and 14/15 sustained TI through last follow-up (up to 9 years). One patient no longer meets protocol-defined TI as a result of Hb level <9g/dL at year 6 due to acute health events unrelated to β-thalassemia, which were not attributed to loss of beti-cel treatment effect. Among all 63 patients, ≈80% of pediatric and adult patients required only 1 mobilization cycle to achieve the DP dose. Median percentage of transduced DP cells was comparable between adult and pediatric populations (78% and 80%, respectively), as were month 6 median peripheral blood vector copy number (1.4 c/dg and 1.1 c/dg) and HbAT87Q (9.4 g/dL and 8.3 g/dL). Overall, 12/63 (19.0%) patients experienced ≥1 beti-cel–related adverse event (AE); beti-cel–related AEs occurring in ≥3 patients included abdominal pain (5/63 [7.9%]) and thrombocytopenia (3/63 [4.8%]). Five patients experienced serious veno-occlusive liver disease; all 5 received defibrotide and recovered. No malignancies, insertional oncogenesis, or vector-derived replication-competent lentivirus were reported. Beti-cel is a potentially curative gene therapy for patients with TDT across ages and genotypes through achievement of TI and normal or near-normal Hb. These data will inform real-world beti-cel treatment decisions for patients with TDT.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
reerwt完成签到,获得积分20
5秒前
20秒前
陈元元K完成签到,获得积分10
26秒前
英俊的铭应助科研通管家采纳,获得10
30秒前
小二郎应助科研通管家采纳,获得10
30秒前
34秒前
梦梦发布了新的文献求助10
39秒前
43秒前
caca完成签到,获得积分0
44秒前
科研通AI2S应助YYYCCCCC采纳,获得10
1分钟前
海鸥别叫了完成签到 ,获得积分10
2分钟前
云霞完成签到 ,获得积分10
2分钟前
朴素的山蝶完成签到 ,获得积分10
2分钟前
2分钟前
FashionBoy应助科研通管家采纳,获得10
2分钟前
Bugs完成签到,获得积分10
2分钟前
2分钟前
小八统治世界完成签到 ,获得积分10
2分钟前
tang完成签到,获得积分10
3分钟前
汉堡包应助舒服的觅夏采纳,获得10
3分钟前
suicone完成签到,获得积分10
3分钟前
zqq完成签到,获得积分0
3分钟前
3分钟前
归陌完成签到 ,获得积分10
3分钟前
3分钟前
mmyhn发布了新的文献求助10
4分钟前
4分钟前
Dave发布了新的文献求助10
4分钟前
4分钟前
科研通AI2S应助科研通管家采纳,获得10
4分钟前
4分钟前
wbs13521完成签到,获得积分0
5分钟前
5分钟前
儒雅致远发布了新的文献求助10
5分钟前
5分钟前
Hello应助儒雅致远采纳,获得10
5分钟前
正在获取昵称中...完成签到,获得积分10
5分钟前
5分钟前
爆米花应助xiongdi521采纳,获得10
6分钟前
6分钟前
高分求助中
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
A new approach to the extrapolation of accelerated life test data 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
基于可调谐半导体激光吸收光谱技术泄漏气体检测系统的研究 350
Robot-supported joining of reinforcement textiles with one-sided sewing heads 320
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3990045
求助须知:如何正确求助?哪些是违规求助? 3532108
关于积分的说明 11256354
捐赠科研通 3270943
什么是DOI,文献DOI怎么找? 1805146
邀请新用户注册赠送积分活动 882270
科研通“疑难数据库(出版商)”最低求助积分说明 809228